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Abstract We have examined the possible role of the F17R 
protein in vaccinia virus-induced rearrangements of the host actin 
cytoskeleton. F17R is localized to vaccinia-induced actin tails 
late during infection. The recombinant vaccinia strain v R O l l k is 
able to induce actin tails that are indistinguishable from controls 
in the absence of F17R expression. The association of vaccinia 
and myxoma virus F17R with the actin cytoskeleton in the 
absence of additional viral factors suggests a basic region in the 
N-terminal half of the protein is important for this interaction. A 
peptide corresponding to this region efficiently bundles actin 
filaments in vitro, confirming that the protein interacts directly 
with actin. Our results show F17R is not required for actin tail 
formation and highlight the difficulty in discriminating functional 
actin-binding proteins from those that associate by virtue of their 
basic nature. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
For many years it has been recognized that viral transfor-
mation results in disruption of the actin cytoskeleton and the 
loss of actin stress fibres [1,2]. However, a number of obser-
vations suggest that many viruses are able to interact with or 
modify the actin cytoskeleton of the host for their own pur-
poses [3]. Of all the viruses that interact with the host actin 
cytoskeleton is vaccinia virus the most studied and character-
ized [4-12]. Recently original morphological studies on the 
effects of vaccinia on the actin cytoskeleton have been as-
cribed a function [9]. The intracellular enveloped form of 
vaccinia virus is able to nucleate the polymerization of actin 
filaments from its membrane surface into a structure known 
as an actin tail [9]. Video analysis shows that viral particles 
move throughout the cytoplasm at a rate of ~ 3 μηι/piιίη 
propelled on the tip of intracellular actin tails [9]. U p o n con-
tact with the plasma membrane, virus particles extend from 
the cell on the tips of microvilli-like projections into neigh-
bouring cells to continue their spread [9,10]. Vaccinia-induced 
actin tails are strikingly similar to those seen in Listeria, Shi-
gella and Rickettsia infections [13,14], suggesting that patho-
gens have developed a common mechanism to exploit the 
actin cytoskeleton to facilitate their spread between cells [9]. 
In contrast to bacterial systems the viral protein required for 
the formation of vaccinia actin tails is currently unknown. 
However, during initial studies on the interaction of vaccinia 
virus with the actin cytoskeleton, a basic 11 k D a viral protein 
was identified that associated with the actin cytoskeleton when 
virus assembly was inhibited [6]. Using a combination of map-
ping and sequencing, p l l was identified as the product of the 
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F17R open reading frame of vaccinia [15-18]. Given the asso-
ciation of F17R with the actin cytoskeleton, we have exam-
ined its possible role in vaccinia actin tail formation. 
2. Materials and methods 
2.1. Cells, vaccinia virus strains and infections 
HeLa cells were infected with vaccinia virus strain WR as described 
previously [9]. HeLa cells were also infected with the recombinant 
vaccinia virus strain vROllk, in which expression of F17R is IPTG 
inducible [19]. HeLa cells were infected with vROllk at a multiplicity 
of infection of 0.1 plaque-forming unit per cell to ensure infection 
volumes were small to avoid potential carry over of IPTG from the 
virus stock which is maintained in 5 mM IPTG. The potential carry 
over of IPTG was calculated to be less than 2.5 μΜ during infection 
which is not expected to induce expression of F17R [19,20]. In addi-
tion, after infection, cells were washed extensively to remove any 
contaminating IPTG. In control experiments IPTG was added to 
the culture medium to a final concentration of 250 μΜ or 5 mM. 
2.2. Antibodies, Western analysis and immunofluorescence 
Infected HeLa cells were labelled with the anti-vaccinia C3 antibody 
[21], anti-pll kDa antisera [6] or anti-F17R antibody [22]. HA-tagged 
mFl7R was detected with anti-HA monoclonal antibody (clone 12CA5) 
(Boehringer Mannheim, Germany). Actin filaments were labelled with 
rhodamine phalloidin (Molecular Probes, Eugene, OR). For immuno-
fluorescence analysis, cells were fixed 8 h postinfection and labelled with 
the indicated antibody and rhodamine phalloidin as described previ-
ously [23]. When cells were pre-extracted, to reduce the cytoplasmic 
background, they were washed once with PHGM (60 mM K-PIPES, 
pH 6.8, 25 mM HEPES, 2 mM MgAc and 1 mM EGTA) at 37°C and 
incubated for 2 min at room temperature in PHGM containing 0.1% 
Triton X-100 and 5 μΜ phalloidin. Extractions were also performed in 
PHGM containing 50-200 mM NaCl and EGTA was replaced by 1 mM 
CaCl2. In double labeling experiments, phalloidin was replaced by rho-
damine-labelled phalloidin at the same concentration. After detergent 
extraction, cells were washed twice for 30 s in PHGM before fixation for 
10 min at room temperature in PHGM containing 3% para-formalde-
hyde. Fixed cells were quenched in 50 mM NH4CI2 in PBS for 15 min at 
room temperature, blocked for 30 min at room temperature in 1% BSA 
in TBS and subsequently processed as described above [23]. Immuno-
fluorescence images were recorded using the EMBL confocal micro-
scope facility and the resulting digital images annotated and merged 
using the Adobe 3.0 software package. 
2.3. Construction of the expression vectors CB6BSKX, CB6NHA and 
CB6CHA 
The Kpn\ to Xba\ pBluescript SK II polylinker was inserted into 
polylinker of CB6 [24] to generate the mammalian expression vector 
CB6BSKX. The HA protein sequence YPYDVPDYA optimized for 
mammalian codon usage was inserted into CB6BSKX in the following 
way. pBluescript SK II was used as a PCR template together with the 
T3 or T7 vector primer in conjunction with a specific N- or C-terminal 
HA primer using the EXPAND high-fidelity TAQ polymerase system 
(Boehringer, Mannheim). The resulting PCR products were cloned 
into CB6BSKX to generate the N- and C-terminal HA-tagged vectors, 
CB6NHA and CB6CHA, the polylinker sequence of which were con-
firmed by sequencing (Fig. 1). 
2.4. Construction of F17R and mF17R expression constructs 
An in-frame Ä/jnl-Kozak consensus sequence was inserted immedi-
ately adjacent to the endogenous initiator MET of F17R or mF17R 
and a double-stop EcoRl site after the last codon by PCR. The PCR 
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BgL II Kpn I Xba I Bam HI 
C B 6 B S K X CMV PROMOTER AGATCTGGTACC BS Polylinker TCTAGAGGATCCCGGG hGH Term and Poly A 
CB6NHA 
BgL I I Kpn I M Y P Y D V P D Y A N o t I Xho I X b a I Bam HI 
PROMOTER AGATCTGGTACCACCATGTACCCCTACGACGTGCCCGACTACGCCGGCGGCCGCCTCGAG BS P o l y l i n k e r TCTAGAGGATCCCGGG hGH T e r m 
HA EPITOPE TAG 
CB6CHA 
BgL I I Kpn I ECOR I N o t I Y P Y D V P D Y A STOPS Bam HI 
PROMOTER AGATCTGGTACC BS P o l y l i n k e r GAATTCGCGGCCGCCTACCCCTACGACGTGCCCGACTACGCCTGATAAGGATCCCGGG hGH T e r m 
HA EPITOPE TAG 
Fig. 1. A schematic representation of the polylinker of the expression vector CB6BSKX and the HA epitope fusion vectors CB6NHA and 
CB6CHA. The position of the CMV promoter as well as the transcription termination and polyadenylation signals from the human growth 
hormone gene (hGH term) are indicated. The sequences of restriction sites flanking the pBluescript SK II-derived polylinker and the HA epit-
ope tag are indicated. For CB6NHA the Kozak consensus, initiator ATG and the NotI site fusion are indicated in bold while in CB6CHA 
Not\ site fusion and termination codons are highlighted in bold. 
products from both reactions were cloned into the Kpnl-EcoRl sites 
of CB6BSKX. N-terminal HA-tagged mF17R was constructed by 
inserting an in-frame Notl site immediately adjacent to the endoge-
nous initiator MET and a double-stop EcoRI site by PCR. The re-
sulting PCR product was cloned into the Notl-EcoRl sites of 
CB6NHA. The expression constructs CB6F17R, CB6MF17R and 
CB6HAMF17R were identified by PCR and their fidelity confirmed 
by sequencing with vector primers prior to transfection into HeLa 
using a standard a calcium phosphate method. 
2.5. In vitro actin peptide bundling assays 
The peptide 6/60, corresponding to residues 6-60 of vaccinia virus 
F17R was synthesised and purified by reverse-phase HPLC. The fidel-
ity of the 6/60 peptide sequence was confirmed by MASS spectrome-
try. Monomeric non-muscle actin obtained from Cytoskeleton (Den-
ver, CO) was polymerized by a 10-fold dilution in F-actin buffer (10 
mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM MgCl2, 0.1 mM ATP, 
0.1 mM DTT, 0.1 mM CaCl2 and 1 mM azide) to a working dilution 
of 1 mg/ml. The 6/60 peptide was also reconstituted in F-actin buffer 
Fig. 2. F17R is localized to vaccinia-induced actin tails. A,D: Localization of F17R with anti-F17R serum; B: Actin filaments visualized by 
rhodamine phalloidin and E viral particles labelled with anti-P14. C,F: Merged false colour images of F17R (A,D) and F-actin (B) or P14 (E). 
The insert in (F) shows F17R (green) is only found in the actin tail and not on the surface of the viral particle (red). Scale bar: 20 μpiι. 
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to a stock solution of 1 mg/ml (165.6 μΜ). Actin filaments were 
diluted to a final concentration of 0.2 mg/ml (4.78 μΜ) in F-actin 
buffer containing 0.0, 5.0, 10.0, 20.0 or 40 μΜ 6/60 peptide. Alter-
natively non-muscle monomeric actin was polymerized to a final con-
centration of 0.2 mg/ml by direct addition to 0.0, 5.0, 10.0, 20.0 or 
40 μΜ 6/60 peptide in F-actin buffer. All samples were incubated for 
30 min at 4°C prior to absorption to a carbon-coated electron micro-
scope grid followed by negative staining with 2% uranyl acetate. Grids 
were examined in a Philips 400 at an accelerating voltage of 80 kV. 
3. Results 
3.1. F17R is localized to vaccinia-induced actin tails but is not 
required for their formation 
By immunofluorescence F17R is undetectable in HeLa cells 
using either anti-pll or anti-F17R antibody (data not shown). 
In vaccinia-infected cells, F17R is found concentrated around 
the nucleus in viral factories as well as throughout the cyto-
plasm (Fig. 2). In addition, F17R is localized to vaccinia-in-
duced actin tails in the cytoplasm as well as in projections at 
the plasma membrane (Fig. 2). Merged images show F17R is 
localized along the complete length of the actin tail and is not 
associated with the viral particle (Fig. 2). To address whether 
F17R initiates actin tail assembly, we examined the ability of 
the vaccinia strain vROllk to form actin tails (Fig. 3). As 
previously observed, there was a severe decrease in the num-
ber of particles in the absence F17R expression as judged 
from anti-P14 immunofluorescence (data not shown). How-
ever, those viral particles that did form were able to induce 
actin tails indistinguishable from controls (Fig. 3). It was no-
ticeable that F17R was localized to viral factories and not 
actin tails even when present at moderate concentrations in 
the cytoplasm (Fig. 3). Only in cells with high cytoplasmic 
concentrations does F17R associate with actin tails suggesting 
a critical concentration is required for the interaction (Fig. 2). 
Fig. 3. F17R is not required for actin tail formation by vaccinia virus. In the absence of detectable F17R expression (A) vROllk induces actin 
tails (B) in infected HeLa cells. In IPTG-induced vROIlk-infected HeLa cells, F17R is localized in the viral factory region (C) but is undetect-
able in actin tails (D). Scale bar: 20 μpiι. 
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Fig. 4. When expressed in a non-viral background F17R (A) associates with the actin cytoskeleton (B) in actin-rich ruffles and microvilli at the 
cell surface (white arrowheads). When cells are pre-extracted F17R (C) is seen in association with actin stress fibres (D). HA-tagged mF17R 
(E) co-localizes with actin stress fibres (F) in an identical fashion to F17R. Scale bar: 30 μηι. 
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Induces actin filament bundling 
Vacc in ia F 1 7 R MNSH—FASAHTPFYINTKEGRYL·VLKAVKVCDVRTVECEGSKASCVLKVDKPSSPACEKRPSSP-SRCERMNNPG-KQVPFMRTD^1LQNMFAANRDNVASRL·L·N 
I I l i l i l í MM 1111II i 1111 II II I l l l l l l l l I II I I I I I I I HUM II I II I II I 
Myxoma F17R MAHHSVYHT-HTPFYIDTKEGKYLVLKAVKVCDIRTIECSGEKASCVLKVEK-TSPTCDRKPMTPCERAARSSSPQNRGVPFMRTNMLEDLQASNRN-VVSRILG 
Fig. 5. Shows a sequence alignment between vaccinia virus F17R (top) and the myxoma virus F17R homologue (mF17R) (bottom). Identical 
residues are indicated by vertical bars, conserved basic residues are indicated by * under the alignment and the conserved region that induces 
actin bundles in vitro is indicated. 
3.2. F17R co-localizes with actin in the absence of other viral 
proteins 
To examine whether F17R is able to associate with actin in 
the absence of other viral factors, we expressed F17R in HeLa 
cells. Although F17R is localized throughout the cytoplasm, 
examination of the cell surface and leading edge showed a 
strong co-localization of F17R with actin in microvilli, micro-
spikes, filopodia and membrane ruffles (Fig. 4). When cells 
were pre-extracted before fixation to reduce the cytoplasmic 
background, F17R was found co-localized with actin stress 
fibres and at focal adhesions (Fig. 4). F17R remains associ-
ated with the actin cytoskeleton when cells are pre-extracted 
in the presence of calcium or up to 50 mM NaCl but not at 
100 mM NaCl. To obtain further insight into the association 
of F17R with actin we expressed the myxoma virus F17R 
homologue in HeLa cells. The sequence of the myxoma virus 
F17R homologue (here termed mF17R) is the most divergent 
F17R sequence available having only an overall ~ 4 8 % iden-
tity, compared to the F17R sequence from vaccinia virus (Fig. 
5). We were unable to detect expression of MF17R in trans-
fected cells with anti-F17R which is not surprising given the 
sequence differences at the C-terminus (data not shown). To 
overcome this problem we generated an N-terminal HA-
tagged mF17R construct. When expressed in cells HA-tagged 
mF17R is found co-localized with the actin cytoskeleton in an 
identical fashion to F17R (Fig. 4). The sequence divergence of 
MF17R and its association with actin suggests that a basic 
region in the N-terminal half of F17R, which has no similarity 
to any known actin-binding protein, is likely to be important 
for actin interactions (Fig. 5). 
3.3. F17R bundles actin filaments in vitro 
To address whether F17R binds directly to actin via the 
conserved basic region in the N-terminal half of the molecule 
we expressed F17R in E. coli to facilitate in vitro actin-bind-
ing assays. Although many different growth and induction 
conditions were examined, we were unable to obtain F17R 
in a soluble form. As an alternative, we synthesised a peptide 
6/60 corresponding the conserved basic region in F17R and 
mF17R (Fig. 5). Samples of actin filaments in the absence of 
the 6/60 peptide were in loose tangles or single filaments and 
no bundles were evident (Fig. 6). Addition of the 6/60 peptide 
to actin filaments initially resulted in disappearance of single 
actin filaments and the formation of loose disordered actin 
bundles. At higher peptide concentrations tight bundles with 
no obvious order were formed (Fig. 6). This supports the 
suggestion that the conserved basic region in the N-terminus 
of F17R is responsible for the association of the protein with 
the actin cytoskeleton. 
4. Discussion 
It is clear that the actin cytoskeleton plays an important 
role during the life cycle of many different pathogens includ-
Fig. 6. The 6/60 peptide induces actin filaments to bundle. In the absence of peptide actin filaments appear as single filaments in a loose net-
work (A). A 2:1 molar ratio of 6/60 peptide to actin results in bundle formation but isolated filaments are still visible (B). At a 4:1 molar ratio 
of 6/60 peptide to actin all filaments have been induced to form compact bundles (C). Scale bar: 100 nm. 
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ing viruses [3,14,25]. In the most extreme cases, pathogens are 
able to recruit host cytoskeletal factors which induce the pol-
ymerization of actin filaments from their surface into a struc-
ture known as a 'tail' [13,14]. Actin polymerization is then 
used as the driving force to propel the pathogen into neigh-
bouring cells to continue the spread of infection. We have 
recently shown that the intracellular enveloped form of vacci-
nia virus is also capable of inducing actin tails that are strik-
ingly similar to those seen in bacterial pathogens such as 
Listeria and Shigella [9]. However, in contrast to Listeria 
and Shigella the protein required to initiate tail formation is 
unknown in the vaccinia system. As a first step to identify 
viral components involved in the actin-based motility of vac-
cinia we have analyzed the role and actin-binding properties 
of F17R. Although F17R is associated with vaccinia-induced 
actin tails our observations with the recombinant vaccinia 
virus strain vROllk clearly demonstrate that it is not required 
for actin tail formation. Given that the primary function of 
F17R is in viral particle morphogenesis, the exact nature of 
which remains to be established [19,20], why does the protein 
associate with the actin cytoskeleton? 
Recently, it has been shown that basic polypeptides are able 
to induce the formation of actin bundles in vitro by virtue of 
their polyelectrolyte nature in an analogous manner to DNA 
condensation [26]. We believe our observations with F17R 
suggest a similar mechanism for its association with the actin 
cytoskeleton. Firstly, F17R is extremely basic with a predicted 
isoelectric point (pi) of 9.6. Secondly, based on pre-extraction 
of transfected cells in increasing salt concentrations that are 
well below physiological levels, F17R has a relatively weak 
interaction with the actin cytoskeleton in vivo. Consistent 
with this observation F17R only associates with actin tails 
when expressed at high levels upon induction in the recombi-
nant vaccinia virus strain vROllk. Thirdly, mF17R from 
myxoma virus, which also associates with actin, is extremely 
basic with a predicted pi of 9.1. Finally, in vitro the 6/60 
peptide induces actin bundles at a peptide/actin concentration 
ratio comparable to the values for other positively charged 
peptides and not to functional actin bundling proteins such 
as villin and fimbrin [26,27]. The fact that the 6/60 peptide 
induces actin bundles which are not ordered also reflects a 
lack of specific contact sites and filament packing constraints 
that are normally seen with functional actin bundling pro-
teins. Taken together, our observations suggest that the asso-
ciation of F17R with the actin cytoskeleton is a consequence 
of its basic nature and not through the interaction of a specific 
binding site. This type of interaction may nonetheless exert an 
effect on the actin cytoskeleton. F17R would be expected to 
enhance the density of actin in the tail by promoting bundling 
between closely opposed actin filaments. We also believe the 
bundling effect of F17R would account for the increase in 
actin-rich microvilli, microspikes, filopodia and membrane 
ruffles seen when the protein is transfected into cells (Fig. 4). 
F17R is not the first protein to bind actin in addition to its 
primary role. Elongation factor EFl-ot, which is also basic 
with a pi of ~ 9.0, bundles actin and associates with the actin 
cytoskeleton although it is critically required for translation 
[28]. While further characterization of F17R during viral in-
fection is required to delinate its role in viral morphogenesis, 
it is clear that the protein plays no role in actin tail formation. 
Our observations with F17R highlight the difficulty in distin-
guishing functional actin-binding proteins from those that as-
sociate purely by virtue of their basic nature and may offer a 
possible explaination why so many actin-binding proteins 
have been identified. 
Acknowledgements: We would like to thank Dr. Gerhard Hiller 
(Boehringer Mannheim, Germany) for anti-11 kDa antibody; Dr. 
Jacomine Krijnse Locker (EMBL) for anti-F17R; Drs. Colleen Brew-
er and Michael Roth (University of Texas Southwestern Medical 
Center, Dallas, TX) for the CB6 expression vector and Dr. Chris 
Upton (University of Victoria, Victoria, Canada) for Myxoma virus 
DNA. We would also like to thank Dr. Bernard Moss (National 
Institute of Allergy and Infectious Dieseases, Bethesda, MD) for the 
recombinant vaccinia virus strain vROllk and discussions concerning 
F17R. We would like to thank Drs. Gareth Griffiths, Jacomine 
Krijnse Locker, Violaine Moreau, Chris Sanderson, and Karen Wil-
liams for comments on the manuscript. 
References 
[1] R. Pollack, M. Osborn, K. Weber, Proc. Nati. Acad. Sei. USA 72 
(1975) 994-998. 
[2] M. Verderame, D. Alcorta, M. Egnor, K. Smith, R. Pollack, 
Proc. Nati. Acad. Sei. USA 77 (1980) 6624-6628. 
[3] Cudmore, S., Reckmann, I. and Way, M. (1997) Trends Micro-
biol. in press. 
[4] G. Hiller, K. Weber, L. Schneider, C. Parajsz, C. Jungwirth, 
Virology 98 (1979) 142-153. 
[5] G. Hiller, C. Jungwirth, K. Weber, Exp. Cell. Res. 132 (1981) 81-
87. 
[6] G. Hiller, K. Weber, J. Virol. 44 (1982) 647-657. 
[7] U. Krempien, L. Schneider, G. Hiller, K. Weber, E. Katz, C. 
Jungwirth, Virology 113 (1981) 556-564. 
[8] L.G. Payne, K. Kristensson, Arch. Virol. 74 (1982) 11-20. 
[9] S. Cudmore, P. Cossart, G. Griffiths, M. Way, Nature 378 (1995) 
636-638. 
[10] S. Cudmore, I. Reckmann, G. Griffiths, M. Way, J. Cell Sei. 109 
(1996) 1739-1747. 
[11] R.K. Meyer, M.M. Burger, R. Tschannen, R. Schäfer, Arch. 
Virol. 67 (1981) 11-18. 
[12] G.V. Stokes, J. Virol. 18 (1976) 636-643. 
[13] P. Cossart, Curr. Opin. Cell Biol. 7 (1995) 94-101. 
[14] J.A. Theriot, Ann. Rev. Cell. Dev. Biol. 11 (1995) 213-239. 
[15] R. Wittek, M. Hanggi, G. Hiller, J. Virol. 49 (1984) 371-378. 
[16] C. Bertholet, R. Drillien, R. Wittek, Proc. Nati. Acad. Sei. USA 
82 (1985) 2096-2100. 
[17] S.J. Goebel, G.P. Johnson, M.E. Perkus, S.W. Davis, J.P. Wins-
low, E. Paoletti, Virology 179 (1990) 247-266. 
[18] G.P. Johnson, S.J. Goebel, E. Paoletti, Virology 196 (1993) 381-
401. 
[19] Y.F. Zhang, B. Moss, Proc. Nati. Acad. Sei. USA 88 (1991) 
1511-1515. 
[20] Y.F. Zhang, B. Moss, J. Virol. 65 (1991) 6101-6110. 
[21] J.F. Rodriguez, R. Janeczko, M. Esteban, J. Virol. 56 (1985) 
482-488. 
[22] O.N. Jensen, T. Houthaeve, A. Shevchenko, S. Cudmore, T. 
Ashford, M. Mann, G. Griffiths, J. Krijnse Locker, J. Virol. 70 
(1996) 7485-7497. 
[23] Herzog, M., Draeger, A., Ehler, E. and Small, J.V. (1994) Cell 
biology: a laboratory handbook, Academic Press, San Diego, 
CA. 
[24] C.B. Brewer, Methods Cell Biol. 43 (1994) 233-245. 
[25] S. Higley, M. Way, Curr. Opin. Cell Biol. 9 (1997) 62-69. 
[26] J.X. Tang, P.A. Janmey, J. Biol. Chem. 271 (1996) 8556-8563. 
[27] P. Matsudaira, Trends Biochem. Sei. 16 (1991) 87-92. 
[28] G. Liu, B.T. Edmonds, J. Condeelis, Trends Cell Biol. 6 (1996) 
168-171. 
